摘要
目的:探求采用头孢哌酮钠舒巴坦钠治疗社区获得性肺炎的效果。方法:选取本院2017年5月—2018年5月收治的社区获得性肺炎患者88例,按随机数字表法分为对照组和试验组,各44例。对照组采用左氧氟沙星(0.3 g静脉滴注,qd)治疗,在此基础上,试验组加用头孢哌酮钠舒巴坦钠(2 g加入100 mL 0.9%氯化钠注射液中静脉滴注,bid)治疗。连续治疗2周后,比较两组临床疗效、炎性细胞因子和呼出气一氧化氮(FeNO)水平及安全性。结果:试验组总有效率较对照组高,差异有统计学意义(P <0.05);治疗后,试验组肿瘤坏死因子(TNF)-α、白细胞介素(IL)-10、IL-6、FeNO水平均较对照组低,差异有统计学意义(P <0.05);两组不良反应发生率比较,差异无统计学意义(P> 0.05)。结论:头孢哌酮钠舒巴坦钠治疗社区获得性肺炎可提升临床疗效,减轻气道及全身炎性反应,且安全性高。
Objective:To explore the efficacy of cefoperazone sodium and sulbactam sodium in the treatment of community-acquired pneumonia.Methods:88 patients with community-acquired pneumonia admitted to our hospital from May 2017 to May 2018 were selected and randomly divided into a control group and an experimental group,44 cases each.The patients in the control group were treated with levo?oxacin(0.3 g for intravenous drip,qd).On this basis,the patients in the experimental group were treated with cefoperazone sodium and sulbactam sodium(2 g drugs were added to 100 mL 0.9%sodium chloride injection,intravenous infusion,bid).After 2 weeks of continuous treatment,the clinical efficacy,the levels of in?ammatory cytokines and fractional exhaled nitric oxide(FeNO)and safety were compared between the two groups.Results:The total effective rate in the experimental group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of tumor necrosis factor(TNF)-α,interleukin(IL)-10,IL-6 and FeNO in the experimental group were lower than those in the control group,and the differences were statistically signi?cant(P<0.05).There was no statistically signi?cant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Cefoperazone sodium and sulbactam sodium can improve clinical efficacy and reduce airway and systemic in?ammatory response in the treatment of community-acquired pneumonia,and have high safety.
作者
冯静
李姗
王娜
朱卫华
杜志强
Feng Jing;Li Shan;Wang Na;Zhu Wei-hua;Du Zhi-qiang(Zhengzhou Yihe Hospital Affiliated to Henan University,Zhengzhou Henan 450000,China;Teaching and Research Section of Pathology and pathophysiology,Basic Medical College of Henan University of Chinese Medicine,Zhengzhou Henan 450046,China)
出处
《中国合理用药探索》
CAS
2019年第5期165-167,171,共4页
Chinese Journal of Rational Drug Use